Boehringer Ingelheim Adds Phase II Anti-Inflammatory Drug to its Respiratory Disease Pipeline
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 31 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1786 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Boehringer Ingelheim has acquired global rights to Funxional Therapeutics’ Phase II oral anti-inflammatory drug FX125L, a potential first-in-class somatotaxin, as well as a somatotaxin development programme...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS